Pub Date : 2024-07-23DOI: 10.1007/s40674-024-00216-4
M. D. de Aguiar, Andressa Miozzo Soares, Alexandre Wagner Silva de Souza
{"title":"Vascular Interventions in Takayasu Arteritis","authors":"M. D. de Aguiar, Andressa Miozzo Soares, Alexandre Wagner Silva de Souza","doi":"10.1007/s40674-024-00216-4","DOIUrl":"https://doi.org/10.1007/s40674-024-00216-4","url":null,"abstract":"","PeriodicalId":11096,"journal":{"name":"Current Treatment Options in Rheumatology","volume":"101 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141812320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-23DOI: 10.1007/s40674-024-00215-5
Johan W. J. Donkers, Robert A. Feijen, Abraham Rutgers
{"title":"(Levamisole Adulterated) Cocaine-Induced Vasculitis: What Is Known/Current Evidence","authors":"Johan W. J. Donkers, Robert A. Feijen, Abraham Rutgers","doi":"10.1007/s40674-024-00215-5","DOIUrl":"https://doi.org/10.1007/s40674-024-00215-5","url":null,"abstract":"","PeriodicalId":11096,"journal":{"name":"Current Treatment Options in Rheumatology","volume":"122 35","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141812033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-10DOI: 10.1007/s40674-023-00214-y
Kevin Gourbeyre-Masson, O. Landon-Cardinal, Olivier Benveniste, Yves Allenbach
{"title":"Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Where Are We?","authors":"Kevin Gourbeyre-Masson, O. Landon-Cardinal, Olivier Benveniste, Yves Allenbach","doi":"10.1007/s40674-023-00214-y","DOIUrl":"https://doi.org/10.1007/s40674-023-00214-y","url":null,"abstract":"","PeriodicalId":11096,"journal":{"name":"Current Treatment Options in Rheumatology","volume":"6 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139440194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01Epub Date: 2023-07-13DOI: 10.1007/s40674-023-00210-2
Sandra Amara Ogbonnaya-Whittlesey, Dale Kobrin, Maria Casal-Dominguez, Andrew L Mammen, Iago Pinal-Fernandez
Purpose of review: Immune-mediated necrotizing myositis (IMNM) is a rare autoimmune disorder characterized by proximal muscle weakness, elevated creatine kinase levels, and necrosis of muscle fibers. While the exact pathogenesis of IMNM remains unknown, anti-HMGCR and anti-SRP autoantibodies are associated with different predisposing factors, clinical manifestations, and severity of the disease and are believed to correspond to two pathogenically distinct entities. The cornerstone treatment for IMNM is a combination of glucocorticoids and steroid-sparing agents. Therapeutic strategies aimed at decreasing the half-life of endogenous autoantibodies, such as intravenous immunoglobulin (IVIG), or reducing their production, such as rituximab, have shown promise as powerful treatments. In severe cases, combining IVIG and rituximab can have synergistic effects.
Recent findings: Previous studies suggested that complement dysregulation may be involved in the pathogenesis of IMNM. However, a recent phase 2 clinical trial evaluating the effectiveness of zilucoplan, a C5 inhibitor, failed to show efficacy in IMNM.
Summary: In this review, we aim to provide a comprehensive review of IMNM focusing on the current evidence regarding treatment options for this condition. Our goal is to present an up-to-date overview of the current state of therapeutics on IMNM and highlight potential areas for future investigation.
{"title":"Treatment of Immune-Mediated Necrotizing Myopathy.","authors":"Sandra Amara Ogbonnaya-Whittlesey, Dale Kobrin, Maria Casal-Dominguez, Andrew L Mammen, Iago Pinal-Fernandez","doi":"10.1007/s40674-023-00210-2","DOIUrl":"10.1007/s40674-023-00210-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>Immune-mediated necrotizing myositis (IMNM) is a rare autoimmune disorder characterized by proximal muscle weakness, elevated creatine kinase levels, and necrosis of muscle fibers. While the exact pathogenesis of IMNM remains unknown, anti-HMGCR and anti-SRP autoantibodies are associated with different predisposing factors, clinical manifestations, and severity of the disease and are believed to correspond to two pathogenically distinct entities. The cornerstone treatment for IMNM is a combination of glucocorticoids and steroid-sparing agents. Therapeutic strategies aimed at decreasing the half-life of endogenous autoantibodies, such as intravenous immunoglobulin (IVIG), or reducing their production, such as rituximab, have shown promise as powerful treatments. In severe cases, combining IVIG and rituximab can have synergistic effects.</p><p><strong>Recent findings: </strong>Previous studies suggested that complement dysregulation may be involved in the pathogenesis of IMNM. However, a recent phase 2 clinical trial evaluating the effectiveness of zilucoplan, a C5 inhibitor, failed to show efficacy in IMNM.</p><p><strong>Summary: </strong>In this review, we aim to provide a comprehensive review of IMNM focusing on the current evidence regarding treatment options for this condition. Our goal is to present an up-to-date overview of the current state of therapeutics on IMNM and highlight potential areas for future investigation.</p>","PeriodicalId":11096,"journal":{"name":"Current Treatment Options in Rheumatology","volume":"4 1","pages":"168-178"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12346690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74634949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-02DOI: 10.1007/s40674-023-00212-0
Ana Matas-García, Eugenia Martinez-Hernandez, José César Milisenda
{"title":"Treatment of Myositis Associated With Immune Checkpoint Inhibitors","authors":"Ana Matas-García, Eugenia Martinez-Hernandez, José César Milisenda","doi":"10.1007/s40674-023-00212-0","DOIUrl":"https://doi.org/10.1007/s40674-023-00212-0","url":null,"abstract":"","PeriodicalId":11096,"journal":{"name":"Current Treatment Options in Rheumatology","volume":"16 6","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135935131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.1007/s40674-023-00207-x
Win Min Oo, J. Hunter
{"title":"Intra-articular Therapies for Knee Osteoarthritis: Current Update","authors":"Win Min Oo, J. Hunter","doi":"10.1007/s40674-023-00207-x","DOIUrl":"https://doi.org/10.1007/s40674-023-00207-x","url":null,"abstract":"","PeriodicalId":11096,"journal":{"name":"Current Treatment Options in Rheumatology","volume":"1 1","pages":"99 - 119"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73248154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-19DOI: 10.1007/s40674-023-00208-w
P. Nicolson, M. Holden
{"title":"Patient Preferences and Osteoarthritis Care: What Do We Know About What Patients Want from Osteoarthritis Treatment?","authors":"P. Nicolson, M. Holden","doi":"10.1007/s40674-023-00208-w","DOIUrl":"https://doi.org/10.1007/s40674-023-00208-w","url":null,"abstract":"","PeriodicalId":11096,"journal":{"name":"Current Treatment Options in Rheumatology","volume":"171 1","pages":"120 - 131"},"PeriodicalIF":0.0,"publicationDate":"2023-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89318622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-20DOI: 10.1007/s40674-023-00205-z
James J Young, Julie Rønne Pedersen, Alessio Bricca
Purpose of review: Exercise therapy is the first line treatment for patients with knee and hip osteoarthritis (OA) but is consistently underutilized. In this review, we aim to provide health care professionals with an overview of the latest evidence in the areas of exercise therapy for OA, which can serve as a guide for incorporating the ideal exercise therapy prescription in the overall management plan for their patients with OA.
Recent findings: Evidence continues to be produced supporting the use of exercise therapy for all patients with knee or hip OA. Ample evidence exists suggesting exercise therapy is a safe form of treatment, for both joint structures and the patient overall. Several systematic reviews show that exercise therapy is likely to improve patient outcomes, regardless of disease severity or comorbidities. However, no single type of exercise therapy is superior to others.
Summary: Health care practitioners and patients should be encouraged to incorporate exercise therapy into treatment plans and can be assured of the safety profile and likelihood of improvement in important patient outcomes. Since no single exercise therapy program shows vastly superior benefit, patient preference and contextual factors should be central to the shared decision-making process when selecting and individualising appropriate exercise therapy prescriptions.
{"title":"Exercise Therapy for Knee and Hip Osteoarthritis: Is There An Ideal Prescription?","authors":"James J Young, Julie Rønne Pedersen, Alessio Bricca","doi":"10.1007/s40674-023-00205-z","DOIUrl":"10.1007/s40674-023-00205-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>Exercise therapy is the first line treatment for patients with knee and hip osteoarthritis (OA) but is consistently underutilized. In this review, we aim to provide health care professionals with an overview of the latest evidence in the areas of exercise therapy for OA, which can serve as a guide for incorporating the ideal exercise therapy prescription in the overall management plan for their patients with OA.</p><p><strong>Recent findings: </strong>Evidence continues to be produced supporting the use of exercise therapy for all patients with knee or hip OA. Ample evidence exists suggesting exercise therapy is a safe form of treatment, for both joint structures and the patient overall. Several systematic reviews show that exercise therapy is likely to improve patient outcomes, regardless of disease severity or comorbidities. However, no single type of exercise therapy is superior to others.</p><p><strong>Summary: </strong>Health care practitioners and patients should be encouraged to incorporate exercise therapy into treatment plans and can be assured of the safety profile and likelihood of improvement in important patient outcomes. Since no single exercise therapy program shows vastly superior benefit, patient preference and contextual factors should be central to the shared decision-making process when selecting and individualising appropriate exercise therapy prescriptions.</p>","PeriodicalId":11096,"journal":{"name":"Current Treatment Options in Rheumatology","volume":" ","pages":"1-17"},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9719861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号